entertainment -WSS

entertainment

author：Wikipedia 2025-09-29 07:19:48 Page View：841

Rod Nathan, Ali Urman, and Patrick Nosker on the 2024 Breakthrough Summit East stage. — From left, Rod Nathan, portfolio manager and partner of J. Goldman & Co.; ARK Invest senior analyst Ali Urman; and Patrick Nosker, director of research and partner at Affinity Asset Advisors, discuss biotech investment opportunities at the 2024 STAT Breakthrough Summit East. STAT

Following a blockbuster year of dealmaking and a recent uptick in biotech stocks, top investors see more good news on the horizon.

Driving the momentum? Economics 101.

Biotechs rely on borrowing capital, which is a more tenuous task when interest rates are high. But interest rates have most likely peaked, with Federal Reserve officials signaling earlier this week they expected to make three cuts this year. For public biotechnology startups that have been battered by the market in recent years, this is a very good thing, Rod Nathan, portfolio manager and partner of J. Goldman & Co., said on a panel at STAT’s Breakthrough Summit East in New York on Thursday.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New Covid vaccine is recommended for everyone 6 months or older
Next article： Psychedelics group wrestles with new pharma identity

comprehensive

Affirmative action in medical school literally saved lives

AdobeThepastseveralmonthshavebeengrimforhealthintheU.S.InDecember,theCentersforDiseaseControlandPrev

Diverse clinical trials: Why aren’t we there yet?

KeishaOkaforforSTATClinicaltrialsarecriticaltoadvancinglifesavingmedicationsandtreatments.ButtheU.S.

Dobbs anniversary: the lost opportunity of abortion as health care

NathanHoward/GettyImagesReflectingonthisfirstanniversaryoftheSupremeCourt’sdecisioninDobbstooverturn

Europe sees delivery challenges ahead on Alzheimer's therapies

VialsandpackagingforLeqembi,anewAlzheimer'smedicationapprovedintheU.S.,butnotyetinEurope.Illustratio

entertainment

focus

comprehensive

Europe sees delivery challenges ahead on Alzheimer's therapies